halobetasol

Trade name: ultravate

Small moleculeapproved

Approved

Dec 27, 1990

Halobetasol Propionate is the propionate salt form of halobetasol, a synthetic corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictor activities. Halobetasol, a topical steroid, diffuses across cell membranes to interact with cytoplasmic corticosteroid receptors located in both the dermal and intradermal cells, thereby activating gene expression of anti-inflammatory proteins mediated via corticosteroid receptor response element. Specifically, this agent induces phospholipase A2 inhibitory proteins, which inhibit the release of arachidonic acid, thereby inhibiting the biosynthesis of potent mediators of inflammation, such as prostaglandins and leukotrienes. As a result, halobetasol reduces edema, erythema, and pruritus through its cutaneous effects on vascular dilation and permeability. The initial interaction, however, is due to the drug binding to the cytosolic glucocorticoid receptor. After binding the receptor the newly formed receptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. — NCATS

Clinical trial activity

26 trials · 18 clinical orgs · 1 marketing orgs

Phase 1
4
Phase 2
11
Phase 3
5
Phase 4
10

Earliest trial started Dec 1, 2003 (NCT00865267)

Timeline

1990s

  1. Dec 27, 1990

    Bristol-Myers Squibb — Earliest FDA Approval

  2. Dec 27, 1990

    Bristol-Myers Squibb — NDA Organization

2000s

  1. Jan 1, 2003

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2008

    Earliest Phase 2 Sponsor(trial)

2010s

  1. Jan 1, 2015

    Earliest Phase 3 Sponsor(trial)

Indications

Mechanism of action

Approval history

  • approvedDec 27, 1990

Chemistry & pharmacology

Loading structure…

SMILES

C[C@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CCl
Mol. weight
428.897 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Delivery
Topical
Availability
Prescription Only

Oral

No

Parenteral

No

Topical

Yes

Sources

Also known as

  • 21-chloro diflorasone
  • 21-chloro diflorasone
  • 6 alpha-fluoroclobetasol 17-propionate
  • 6-fluoroclobetasol 17-propionate
  • bmy-30056
  • bmy-30056
  • cgp 14458
  • cgp 14 458
  • cgp-14458
  • cgp-14458
  • cgp-14458
  • halobetasol
  • halobetasol
  • halobetasol
  • halobetasol
  • halobetasol
  • halobetasol propionate
  • halobetasol propionate
  • halobetasol propionate
  • idp-122
  • ulobetasol
  • ulobetasol
  • ulobetasol
  • ulobetasol
  • ulobetasol
  • ulobétasol
  • ulobétasol
  • ulobetasolum
  • ulobetasolum
  • ultravate
  • ultravate
  • ultravate
  • ultravate

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06042647Phase 4Jul 13, 2023Dermatology Consulting Services, High Point NC
NCT05872256Phase 4Jun 1, 2023Dermatology Consulting Services, High Point NC
NCT05608499Phase 3Oct 4, 2022Bausch Health Companies, Icahn School of Medicine at Mount Sinai
NCT05348200Phase 2Apr 22, 2022Citius Pharmaceuticals, Therapeutics, Inc.
NCT05203315Phase 3Jan 17, 2022Austin Institute for Clinical Research
NCT05282771Early Phase 1 (Phase 1)Apr 16, 2021Catawba Clinical Research, Taro Pharmaceuticals
NCT04571151Phase 4Jan 31, 2021University of Tehran
NCT04720105Phase 4Nov 19, 2020Bausch Health Companies, Icahn School of Medicine at Mount Sinai
NCT04119102Phase 4Oct 1, 2019Bausch Health Companies, Windsor Dermatology
NCT03992261Phase 4Jun 14, 2019Mayne Pharma
NCT03988439Phase 4Jun 8, 2019Bausch Health Companies
NCT03987763Phase 4Jun 8, 2019Bausch Health Companies
NCT03298581Phase 2Nov 1, 2017Novum Pharmaceutical Research Services, Sun Pharmaceuticals
NCT03245385Phase 2Jun 29, 2017Novum Pharmaceutical Research Services, Sun Pharmaceuticals
NCT03212963Phase 4Mar 21, 2017Sun Pharmaceuticals, Therapeutics, Inc.
NCT02785185Phase 2Jun 1, 2016Bausch Health Companies
NCT02785172Phase 2Apr 1, 2016Bausch Health Companies
NCT02514577Phase 3Nov 20, 2015Bausch Health Companies
NCT02515097Phase 3Nov 10, 2015Bausch Health Companies
NCT01610596Phase 2Nov 1, 2011Therapeutics, Inc.
Showing 20 of 26 trials
Page 1 / 2

Organizations

Research & Development (18)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Bausch Health CompaniesFor profit9632015
Therapeutics, Inc.For profit4222010
Sun PharmaceuticalsFor profit3322017
ActavisFor profit2212003
Dermatology Consulting Services, High Point NCAcademic/Hospital2212023
DermTech InternationalFor profit2012003
Icahn School of Medicine at Mount SinaiAcademic/Hospital2222020
Novum Pharmaceutical Research ServicesFor profit2012017
Austin Institute for Clinical ResearchFor profit1112022
AzidusFor profit1112008
Catawba Clinical ResearchFor profit1012021
Citius PharmaceuticalsFor profit1112022
Mayne PharmaFor profit1112019
Patel, Rita Vikram, M.D.Academic/Hospital1112011
Taro PharmaceuticalsFor profit1112021
University of California, San FranciscoAcademic/Hospital1112009
University of TehranAcademic/Hospital1112021
Windsor DermatologyAcademic/Hospital1112019
18 organizations
Page 1 / 1

Marketing (1)

OrganizationOrg typeRelationshipDate
Bristol-Myers SquibbFor profitNDADec 27, 1990